Meeting
2023 ASCO Genitourinary Cancers Symposium
Germline DNA damage response (DDR) mutations in an East Asian (EA) cohort with prostate cancer (PCa).
Authors
Joanne Y.H. Lua
Ministry of Health Holdings, Singapore, Singapore, Singapore
Joanne Y.H. Lua , Johan W.K. Chan , Enya H.W. Ong , Melody Chow , Kae-Jack Tay , Jeffrey K.L. Tuan , Michael L.C. Wang , Lui Shiong Lee , Ravindran Kanesvaran , Li Yan Khor , Melvin L.K. Lee Kiang Chua
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 373)
DOI
10.1200/JCO.2023.41.6_suppl.373
Abstract #
373
Poster Bd #
N11
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Prognostic impact of DNA repair germline variants in hormone sensitive prostate cancer stage.
First Author: Manish Kohli
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR).
First Author: Kamal Kant Kant Sahu
Poster
2023 ASCO Genitourinary Cancers Symposium
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
First Author: Channing Judith Paller